MagForce AG : Voluntary Directors' Dealings announcement of Dr. Ben J. Lipps

Berlin, Germany, August 29, 2013 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, announced today that Ben Lipps, designated CEO starting September 1st, 2013, has disclosed to the Company that he has bought 250,000 shares in MagForce, which represents 1.05% of the Company's outstanding shares.

About MagForce AG

MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company's proprietary, NanoTherm^® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm^®, NanoPlan^®, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm^®, NanoPlan^®, and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com:
http://www.magforce.com/.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact:

Anne Hennecke
MC Services AG

T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759


Email: anne.hennecke@mc-services.eu